Skip to main content

Inavolisib + Palbociclib-Fulvestrant Improves Survival in Advanced Breast Cancer

Medically reviewed by Carmen Pope, BPharm. Last updated on Oct 31, 2024.

By Elana Gotkine HealthDay Reporter

THURSDAY, Oct. 31, 2024 -- Inavolisib plus palbociclib-fulvestrant yields significantly longer progression-free survival than placebo plus palbociclib-fulvestrant in patients with PIK3CA-mutated, hormone receptor-positive, human epidermal growth factor receptor 2 (HER2)-negative locally advanced or metastatic breast cancer, according to a study published in the Oct. 31 issue of the New England Journal of Medicine.

Nicholas C. Turner, M.D., Ph.D., from the Royal Marsden Hospital in London, and colleagues conducted a double-blind, randomized trial comparing first-line inavolisib plus palbociclib-fulvestrant (inavolisib group; 161 patients) to placebo plus palbociclib-fulvestrant (placebo group; 164 patients) in patients with PIK3CA-mutated, hormone receptor-positive, HER2-negative locally advanced or metastatic breast cancer who had had a relapse during or within 12 months of adjuvant endocrine therapy completion.

The researchers found that the median progression-free survival was 15.0 and 7.3 months in the inavolisib and placebo groups, respectively (hazard ratio for disease progression or death, 0.43). An objective response occurred in 58.4 and 25.0 percent of patients in the inavolisib and placebo groups, respectively. In the inavolisib and placebo groups, the incidence of grade 3 or 4 neutropenia was 80.2 and 78.4 percent, respectively. The corresponding incidence rates were 5.6 and 0 percent for grade 3 or 4 hyperglycemia; 5.6 and 0 percent for grade 3 or 4 stomatitis or mucosal inflammation; and 3.7 and 0 percent for grade 3 or 4 diarrhea. There was no grade 3 or 4 rash reported. Overall, 6.8 and 0.6 percent of patients in the inavolisib and placebo groups had discontinuation of any trial agent because of adverse events.

"Inavolisib plus palbociclib-fulvestrant may represent a new treatment option for these patients," the authors write.

The study was funded by F. Hoffmann-La Roche, a subsidiary of which manufactures inavolisib (Genentech).

Abstract/Full Text (subscription or payment may be required)

Editorial (subscription or payment may be required)

Disclaimer: Statistical data in medical articles provide general trends and do not pertain to individuals. Individual factors can vary greatly. Always seek personalized medical advice for individual healthcare decisions.

© 2025 HealthDay. All rights reserved.

Posted October 2024

Read this next

Some Triple Negative Breast Cancers Might Be Avoided by Longer Breastfeeding

THURSDAY, May 15, 2025 -- Shorter breastfeeding duration and younger age at first birth are known risk factors for triple negative breast cancer (TNBC) and vary by race, according...

Bilateral Salpingo-Oophorectomy Beneficial in BRCA1/2 Carriers With Personal History of Breast Cancer

TUESDAY, May 13, 2025 -- For carriers of pathogenic variants in BRCA1 and BRCA2 with a personal history of breast cancer, bilateral salpingo-oophorectomy (BSO) is beneficial...

Weight Gain, Late First Pregnancy Combo Increases Breast Cancer Risk

MONDAY, May 12, 2025 -- Weight gain combined with late first pregnancy (FP) or nulliparity is associated with an increased risk for breast cancer (BC), according to a study...

More news resources

Subscribe to our newsletter

Whatever your topic of interest, subscribe to our newsletters to get the best of Drugs.com in your inbox.